3 European Stocks Estimated To Be Up To 47.2% Below Intrinsic Value
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name
Current Price
Fair Value (Est)
Discount (Est)
Westwing Group (XTRA:WEW)
€9.20
€18.21
49.5%
STMicroelectronics (ENXTPA:STMPA)
€22.245
€43.94
49.4%
RVRC Holding (OM:RVRC)
SEK46.12
SEK91.42
49.5%
Laboratorios Farmaceuticos Rovi (BME:ROVI)
€55.55
€109.69
49.4%
KebNi (OM:KEBNI B)
SEK2.75
SEK5.43
49.4%
Echo Investment (WSE:ECH)
PLN5.36
PLN10.70
49.9%
ATON Green Storage (BIT:ATON)
€2.13
€4.22
49.5%
Atea (OB:ATEA)
NOK142.40
NOK282.80
49.6%
adidas (XTRA:ADS)
€198.95
€393.88
49.5%
Absolent Air Care Group (OM:ABSO)
SEK242.00
SEK482.63
49.9%
Click here to see the full list of 197 stocks from our Undervalued European Stocks Based On Cash Flows screener.
Here we highlight a subset of our preferred stocks from the screener.
Lectra
Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, furniture markets, and other industries globally, with a market cap of €986.24 million.
Operations: The company's revenue segments are distributed as follows: €176.26 million from the Americas, €134.84 million from the Asia-Pacific region, and €220.46 million from EMEA (Europe, Middle East, and Africa).
Estimated Discount To Fair Value: 47.2%
Lectra is trading at €25.95, significantly below its fair value estimate of €49.12, suggesting it is highly undervalued based on cash flows. The company's earnings are expected to grow 21.81% annually, outpacing the French market average of 12.7%. Recent strategic initiatives include the expansion of Lectra's Valia platforms into new markets and partnerships with companies like Edgecombe Furniture, enhancing operational efficiency and supporting future growth prospects through innovative solutions in manufacturing automation.
Our growth report here indicates Lectra may be poised for an improving outlook.
Navigate through the intricacies of Lectra with our comprehensive financial health report here.
Pluxee
Overview: Pluxee N.V. provides employee benefits and engagement solutions services across France, Latin America, Continental Europe, and internationally with a market cap of €2.72 billion.
Operations: The company's revenue segments are comprised of €0.47 billion from Latin America, €0.24 billion from the Rest of the World, and €0.55 billion from Continental Europe.
Estimated Discount To Fair Value: 45.4%
Pluxee, trading at €18.69, is significantly undervalued with a fair value estimate of €34.21. Earnings grew by 182.1% last year and are projected to increase by 16.06% annually, surpassing the French market's growth rate of 12.7%. The company confirmed low double-digit revenue growth for fiscal years 2025 and 2026, supported by its resilient business model and strong performance in early fiscal 2025, indicating robust cash flow potential despite modest revenue growth forecasts of 7%.
The analysis detailed in our Pluxee growth report hints at robust future financial performance.
Click here and access our complete balance sheet health report to understand the dynamics of Pluxee.
Vimian Group
Overview: Vimian Group AB (publ) operates in the global animal health industry with a market capitalization of SEK19.52 billion.
Operations: The company's revenue segments consist of Medtech (€142.10 million), Diagnostics (€22.50 million), Specialty Pharma (€178.20 million), and Veterinary Services (€61.60 million).
Estimated Discount To Fair Value: 13.5%
Vimian Group, trading at SEK36.7, is slightly undervalued with a fair value estimate of SEK42.45. The company's earnings grew by 132.6% last year and are expected to grow significantly over the next three years, outpacing the Swedish market's growth rate of 16.9%. Recent earnings reports show strong sales growth from EUR 91 million to EUR 104.3 million in Q2 2025, reflecting robust cash flow potential despite recent executive changes and low forecasted return on equity.
Our expertly prepared growth report on Vimian Group implies its future financial outlook may be stronger than recent results.
Unlock comprehensive insights into our analysis of Vimian Group stock in this financial health report.
Turning Ideas Into Actions
Take a closer look at our Undervalued European Stocks Based On Cash Flows list of 197 companies by clicking here.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Searching for a Fresh Perspective?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:LSS ENXTPA:PLX and OM:VIMIAN.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Here's Why APA Corp. (APA) Shares Pressured in Q2
Hotchkis & Wiley, an investment management company, released its 'Hotchkis & Wiley Large Cap Disciplined Value Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 rose 10.9% in Q2 2025, despite recent volatility. After the "liberation day' tariff announcement on April 2, the index plunged over 12% in four days. The market rebounded from this low, nearly +25% over the next ~11 weeks, to finish the quarter at an all-time high. In this environment, the fund performed in line with the Russell 1000 Value Index and returned 3.37% vs. 3.79% for the index. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second-quarter 2025 investor letter, Hotchkis & Wiley Large Cap Disciplined Value Fund highlighted stocks such as APA Corporation (NASDAQ:APA). APA Corporation (NASDAQ:APA) engages in oil and natural gas exploration, development, and production. The one-month return of APA Corporation (NASDAQ:APA) was 0.97%, and its shares lost 36.90% of their value over the last 52 weeks. On July 29, 2025, APA Corporation (NASDAQ:APA) stock closed at $19.68 per share, with a market capitalization of $7.101 billion. Hotchkis & Wiley Large Cap Disciplined Value Fund stated the following regarding APA Corporation (NASDAQ:APA) in its second quarter 2025 investor letter: "APA Corporation (NASDAQ:APA) is an independent exploration and production (E&P) operating offshore in Midland and Delaware basins in the Permian and onshore Egypt. The company has lucrative financial contracts that allow it to generate significant free cash flow (FCF) from differentials in natural gas prices. Investing in this company provides exposure to an energy market that was underearning versus normal levels of profitability and is currently generating significant FCF in what could be a perennially undersupplied market. Stock performance continued to be pressured throughout the quarter, driven by worries surrounding the Organization of the Petroleum Exporting Countries+ (OPEC+) barrels returning to the market, coupled with slowing demand. We believe that APA is misunderstood as investors are focusing on relatively shorter resource life in the Permian without factoring reinvestment opportunities in Suriname, Egypt, and potentially Alaska." Workers in hard hats and safety gear processing oil and gas in a US refinery. APA Corporation (NASDAQ:APA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held APA Corporation (NASDAQ:APA) at the end of the first quarter, compared to 34 in the previous quarter. While we acknowledge the potential of APA Corporation (NASDAQ:APA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered APA Corporation (NASDAQ:APA) and shared Ariel Focus Fund's views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Here's Why UnitedHealth Group (UNH) is on the Hotchkis & Wiley Large Cap Disciplined Value Fund's Contributors' List
Hotchkis & Wiley, an investment management company, released its 'Hotchkis & Wiley Large Cap Disciplined Value Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 rose 10.9% in Q2 2025, despite recent volatility. After the "liberation day' tariff announcement on April 2, the index plunged over 12% in four days. The market rebounded from this low, nearly +25% over the next ~11 weeks, to finish the quarter at an all-time high. In this environment, the fund performed in line with the Russell 1000 Value Index and returned 3.37% vs. 3.79% for the index. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second-quarter 2025 investor letter, Hotchkis & Wiley Large Cap Disciplined Value Fund highlighted stocks such as UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH) is a diversified healthcare company that operates through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments. The one-month return of UnitedHealth Group Incorporated (NYSE:UNH) was -15.12%, and its shares lost 54.69% of their value over the last 52 weeks. On July 29, 2025, UnitedHealth Group Incorporated (NYSE:UNH) stock closed at $261.07 per share, with a market capitalization of $236.827 billion. Hotchkis & Wiley Large Cap Disciplined Value Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its second quarter 2025 investor letter: "UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation." A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) is in 18th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 139 hedge fund portfolios held UnitedHealth Group Incorporated (NYSE:UNH) at the end of the first quarter, which was 150 in the previous quarter. While we acknowledge the potential of UnitedHealth Group Incorporated (NYSE:UNH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered UnitedHealth Group Incorporated (NYSE:UNH) and shared the list most undervalued blue-chip stocks to buy according to hedge funds. Polen Focus Growth Strategy sold its stake in UnitedHealth Group Incorporated (NYSE:UNH) during Q2 2025 due to reduced guidance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
